Pemafibrate

CAT: 0804-HY-17618-01Size: 5 mgDry Ice: NoHazardous: No
CAT#:0804-HY-17618-01Size:5 mg
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Pemafibrate is a highly selective PPARα agonist, with an EC50 of 1 nM.
CAS Number
[848259-27-8]
Product Name Alternative
(R) -K-13675
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
PPAR
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor
Applications
COVID-19-anti-virus
Field of Research
Inflammation/Immunology; Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/Pemafibrate.html
Purity
99.88
Solubility
DMSO : ≄ 100 mg/mL
Smiles
CC[C@@H](OC1=CC=CC(CN(C2=NC3=CC=CC=C3O2)CCCOC4=CC=C(OC)C=C4)=C1)C(O)=O
Molecular Formula
C28H30N2O6
Molecular Weight
490.55
Precautions
H302, H315, H319, H335
References & Citations
[1]Yamazaki Y, et al. Design and synthesis of highly potent and selective human peroxisome proliferator-activated receptor alpha agonists. Bioorg Med Chem Lett. 2007 Aug 15;17 (16) :4689-93. Epub2007 May 24.|[2]Honda Y, et al. Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis. Sci Rep. 2017 Feb 14;7:42477.|[3]Sairyo M, et al. A Novel Selective PPARα Modulator (SPPARMα), K-877 (Pemafibrate), Attenuates Postprandial Hypertriglyceridemia in Mice. J Atheroscler Thromb. 2018 Feb 1;25 (2) :142-152.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
PPARα; PPARβ/Γ; PPARγ

Related Products

CatalogName

Popular Products